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Despite the mayhem caused by COVID-19, children appear largely 
to have been spared. The disease in children is also more forgiving 
than in adults, and most children experience mild symptoms or are 
asymptomatic.[1-3] While clinical presentation in children is similar 
to that in adults, with symptoms including fever, cough, sneezing, 
sore throat and malaise, progression to more severe lower respiratory 
tract disease is significantly less common. There have been reports of 
gastrointestinal manifestations in children, including diarrhoea and 
vomiting.[4]
Isolated reports of neonates presenting with unusual manifestations 
of sepsis have emerged. Although conflicting reports have indicated 
evidence for[5,6] and against[7,8] vertical transmission of the virus, it 
has not yet been proven to occur.[9] New guidelines released by the 
Council for Medical Schemes suggest that healthy newborn infants of 
infected mothers do not require testing. COVID-19 infection has not 
been added as an indication for caesarean section.[10]
Severe disease in adults results from cytokine release syndrome 
(CRS) or ‘cytokine storm’. There is a dysregulated release of cytokines 
and chemokines, especially interleukin (IL)-2, IL-6, IL-7, IL-10, 
tumour necrosis factor alpha, granulocyte colony-stimulating factor, 
interferon gamma inducible protein 10, monocyte chemotactic 
protein 1 and monocyte inhibitory protein 1A.[11] This deleterious 
hyper-inflammatory state results from a maladaptation of both innate 
and adaptive immune responses, the first line of defence to protect 
individuals from viral infections. In a normal and healthy immune 
response, antiviral immunity would eradicate the pathogen. However, 
in a compromised immune system, this response can result in CRS. 
CRS in adults may potentially progress to acute respiratory distress 
syndrome (ARDS), multi-organ dysfunction and a widespread and 
potentially lethal hypercoagulable state.[12,13] 
ARDS is significantly less common in children. However, one 
significant complication of COVID-19 has emerged in children. 
The first report of an atypical Kawasaki-like syndrome was reported 
in a child in Europe on 28 April 2020.[14] This condition has since 
come to be known as COVID-19-associated paediatric multisystem 
inflammatory syndrome (PMIS).[15] Case definitions have been 
formulated for this syndrome by the Royal College of Paediatrics and 
Child Health in the UK[16] and the Centers for Disease Control in the 
USA.[17] The details can be found in Tables 2 and 3, respectively, of the 
review article in this edition of SAMJ (pp. 864 - 868).[18]
Typical Kawasaki disease (KD), also referred to as mucocutaneous 
lymph node syndrome,[19] is a rare disorder of unknown cause. [19] 
Patients present with a constellation of clinical symptoms 
including persistent fever and mucocutaneous involvement such as 
conjunctivitis, changes in the tongue or oral cavity and oedema of 
the hands and feet, followed by desquamation of the epidermis, a rash 
and cervical lymph node involvement.[19] The cardiac manifestations 
are related to a vasculitis leading to aneurysms of the coronary 
arteries in up to 20% of affected patients, although other blood vessels 
in the body may also be affected. Historically, KD has been seen 
most frequently in Asian countries, and despite exhaustive efforts 
to try to ascertain a cause for the condition, none has been found.[20] 
There is therefore no confirmatory diagnostic test.[21,22] The frequent 
association with an infectious pathogen has led to the hypothesis that 
KD is linked to an immune response to a specific antigen (innate and 
features of adaptive immune responses) in a genetically predisposed 
individual.[20]
PMIS presents in children after the acute phase of infection, 
evidenced in the majority of patients by the presence of SARS-CoV-2 
antibodies and a negative polymerase chain reaction (PCR) test.[22,23] 
In an attempt to determine the possible pathogenesis of the condition 
related to SARS-CoV-2, multiple theories have been postulated. Some 
indicate that, as in SARS-CoV-1, the presence of antibodies may 
increase viral entry into target cells[22] or immune complexes may be 
deposited in tissues including coronary vessels.[22,23] Furthermore, the 
cross-reactivity between a microbial antigen and host tissues, where 
certain proteins are shared (known as molecular mimicry), is also a 
possibility.[24] Finally, McCrindle and Manlhiot[20] posed the question 
whether SARS-CoV-2 may act as a co-stimulatory agent for the actual 
trigger in PMIS/KD.
An initial review of 10 cases of Kawasaki-like disease in Italy 
revealed a 30-fold increase in such cases in the COVID-19 era 
compared with the 5 years preceding COVID-19.[23] This review 
presents compelling indications for a potential association between 
PMIS and COVID-19. This report was followed by those from 
the USA (17 patients),[25] France (2 reports: 21 patients[26] and 
16 patients[27]) and the UK (2 reports: 8 patients[28] and 58 patients[22]), 
with additional reports being added on an ongoing basis. Clinical 
features of PMIS are reported to be similar to KD, although not 
always fulfilling all criteria. Patients usually present with persistent 
high-grade fever (>38.5°C), shock, single- or multiorgan failure, 
skin or mucosal manifestations, and partial or complete fulfilment 
of the KD criteria. Other causes of sepsis as well as myocarditis are 
important to exclude.
Important differences have, however, been noted in the reports 
on PMIS, and must guide the identification of suspected cases 
presenting for medical care. The median age of presentation is older 
than that for classic KD. Patients with PMIS also seem more likely to 
develop severe disease, as evidenced by a higher rate of progression 
to shock, more severe lymphopenia and thrombocytopenia, high 
rates of myocardial dysfunction, and higher levels of inflammatory 
markers such as IL-6, serum ferritin and C-reactive protein. Despite 
the severity, the reported mortality rate remains at 2 - 4%. This 
is encouraging, and supports the advantages to be gained from 
providing urgent treatment.
In a cohort of children with PMIS from France and Switzerland,[29] 
an age range from 2 to 16 years was found. Nearly one-third of 
the children were known to have comorbidities, which included 
asthma and obesity. Most children had gastrointestinal symptoms. 
CRS and macrophage activation were presumed to be present in 
these children. Laboratory investigations yielded high levels of IL-6 
(median 135 pg/mL) and D-dimers (median 5 284 ng/mL). There was 
also a significantly elevated level of brain natriuretic peptide, which 
is thought to be released by cardiomyocytes as a result of ventricular 
stretching when blood volumes increase. In this study,[29] 31 of the 35 
patients (88%) had positive SARS-CoV-2 test results, either by PCR 
or serology. The authors noted that inflammation was not the only 
feature that might be contributing to coronary artery dilatation, and 
proposed that a different mechanism could be at play. One-third of 
the patients had a reduced cardiac ejection fraction. In managing 
these children, inotropic support was required in 80%, and nearly 
one-third required extracorporeal membrane oxygen. Intravenous 
immunoglobins were used to treat all 35 patients, and remained the 
first line of treatment in all other reports describing management of 
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patients with PMIS. One-third of the patients also received adjuvant 
steroid therapy. Pouletty et  al.,[27] in a separate study, reported that 
62% of their cohort required second-line treatment including further 
doses of immunoglobulin, corticosteroids or biological agents.
An important factor that may potentially have direct consequences 
for the South African (SA) population is the predominance of PMIS 
in patients of African ancestry (including African American and 
Afro-Caribbean).[22,26,29] It is not known whether this is secondary to 
a genetic predisposition related to the presence of susceptibility or 
absence of protective genes,[20] or due to other risk factors. What is 
clearly apparent from adult reports in the USA[30] and the UK[31] is a 
worse outcome in patients of African ancestry (and other minorities) 
who develop COVID-19. Again, it is not known whether genetic 
factors play a role or socioeconomic factors are the major contributors 
to the disproportionate mortality. Without knowledge of the potential 
risk in our own society, the diagnosis may be unnecessarily delayed.
In SA, there are currently no data on the number of children 
who have required hospital admission and intensive care. However, 
data from the USA suggest that children aged <1 year have a higher 
hospital and intensive care unit (ICU) admission rate than older 
children,[3,32] probably owing to an immature immune response that 
is ineffective at eradicating the viral pathogen. Additionally, other 
groups potentially at risk include children with underlying immune 
deficiencies (congenital, secondary to malignancy or administration 
of chemotherapy/radiation therapy, post-transplant due to high 
doses of glucocorticoids), underlying lung disease (e.g. asthma), 
cardiovascular disease, chronic kidney disease, diabetes mellitus and 
obesity.[33] More than 80% of children admitted to ICUs in the USA 
were found to have comorbidities.[34] The mortality rate for children 
admitted to a PICU is 5%, which is significantly lower than that 
reported for critically ill adults.
Children are unlikely to be the source of transmission of SARS-
CoV-2, as demonstrated in multiple studies where contact tracing 
has been effectively documented.[35-40] This finding has bearing on 
continued ‘lockdown’, especially of children, and the number of 
unintended collateral damage consequences they experience. Many 
SA children were suffering long before the advent of COVID-19. 
Widespread poverty, lack of access to basic amenities and poor 
socioeconomic status have threatened their health for generations. 
These tribulations, in combination with a fractured healthcare system 
and a fragile economy, have proved to be lethal for the population 
group that is deemed to be the future of SA, the children of this 
country.
In summary, children are seldom infected with severe COVID-
19 and are a highly unlikely source of spread of the virus. If they 
do develop an exaggerated immune response, it may present as an 
atypical Kawasaki-like condition now referred to as PMIS. Cases have 
now been seen in SA, and a high index of suspicion is mandatory. If a 
child is suspected of having this condition, he or she must be referred 
for specialist care in a setting with high-care or intensive care facilities 
for prompt initiation of treatment in order to avoid the morbidity and 
mortality related to this disease.
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